ArticleCardiovascular intervention and therapeutics2026
Right heart function matters: prognostic value of sPAP, TAPSE and RV-PA coupling in a real-world cohort of TAVI patients.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of the TAPSE/sPAP Ratio in Patients with Type 2 Respiratory Failure: Insights into Right Ventricular-Pulmonary Arterial Coupling and Clinical Outcomes.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Right ventricular (RV) function is an established prognostic factor in structural heart disease, but is not routinely incorporated into pre-procedural risk assessment in patients undergoing transcatheter aortic valve implantation (TAVI). This study evaluated the prognostic impact of systolic pulmonary artery pressure (sPAP), tricuspid annular plane systolic excursion (TAPSE), and RV–pulmonary artery (PA) coupling (TAPSE/sPAP ratio) in a real-world TAVI population. This retrospective single-center study included 565 consecutive patients (mean age 82.1 ± 5.1 years; 48.7% male) undergoing transfemoral TAVI between 2016 and 2022. All patients received standardized pre-procedural echocardiographic assessment of sPAP, TAPSE, and TAPSE/sPAP. The primary endpoint was all-cause mortality over a mean follow-up of 47.1 ± 22.8 months. Impaired RV–PA coupling – defined as a TAPSE/sPAP < 0.55 mm/mmHg – was identified in 46.5% of patients, elevated sPAP (≥35 mmHg) in 61.2%, and reduced TAPSE (≤18 mm) in 22.3%. Both elevated sPAP and reduced TAPSE/sPAP were significantly associated with increased long-term mortality (p=0.004 and p<0.001, respectively), whereas TAPSE alone was not predictive (p=0.318). Subgroup and interaction analyses showed that the prognostic impact of sPAP and TAPSE/sPAP was greatest in patients aged ≥80 years, in males, and in those with preserved left ventricular ejection fraction and normal stroke volume index (SVi).RV afterload, as reflected by elevated sPAP and impaired RV–PA coupling, is a key driver of post-TAVI mortality, outperforming isolated RV systolic measurements. The TAPSE/sPAP ratio is a robust, integrative marker whose prognostic value is modulated by age, sex and left heart function. These findings support incorporating RV–PA coupling into routine pre-TAVI assessment to improve risk stratification and identify vulnerable patients before intervention
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.